SCHEMBL353291

SCHEMBL353291

Cc1cccc(C)c1C(=O)N(C)Cc1nsc(NC(=O)NCc2cccc(F)c2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 3/20 0.48
ROCK1 Q13464 2/20 0.48
EPHX2 P34913 1/20 0.46
ATG4B Q9Y4P1 1/20 0.44
NPC1 O15118 1/20 0.43
NAMPT P43490 3/20 0.41
AURKA O14965 1/20 0.40
CDK8 P49336 1/20 0.40
AURKB Q96GD4 1/20 0.40
MAPK1 P28482 1/20 0.40
IDH1 O75874 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PAX8 Q06710 1/20 0.39
NLRP3 Q96P20 1/20 0.39
ANPEP P15144 1/20 0.39
OPRM1 P35372 1/20 0.39
MAPT P10636 3/20 0.39
TP53 P04637 2/20 0.39
CHRM4 P08173 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL353974 0.89 ROCK2 (0.44) ROCK2ROCK1EPHX2ATG4BNPC1
SCHEMBL353621 0.88 ROCK2 (0.43) ROCK2ROCK1EPHX2ATG4BNPC1
SCHEMBL352752 0.88 ROCK2 (0.45) ROCK2ROCK1EPHX2ATG4BNPC1
SCHEMBL353270 0.88 ROCK2 (0.45) ROCK2ROCK1EPHX2ATG4BNPC1
SCHEMBL352803 0.87 ROCK2 (0.44) ROCK2ROCK1EPHX2ATG4BNPC1
SCHEMBL354447 0.86 ROCK2 (0.51) ROCK2ROCK1EPHX2ATG4BNPC1
SCHEMBL352804 0.86 ROCK2 (0.48) ROCK2ROCK1EPHX2ATG4BNPC1
SCHEMBL352957 0.86 ROCK2 (0.43) ROCK2ROCK1EPHX2ATG4BNPC1
SCHEMBL353623 0.85 ROCK2 (0.42) ROCK2ROCK1EPHX2ATG4BNPC1
Cyclopentane SCHEMBL19119283 0.85 ROCK2 (0.50) ROCK2ROCK1EPHX2ATG4BNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP claimed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US claimed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US claimed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP claimed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO claimed
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP disclosed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP disclosed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA ROCK2 4626/4885ROCK1 4747/4885EPHX2 4031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.